Supernus Pharmaceuticals Inc
SWB:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
SWB:S49
|
US |
|
A
|
AIC Mines Ltd
XBER:HLS
|
AU |
|
Franklin Resources Inc
NYSE:BEN
|
US |
|
C
|
Covestro AG
LSE:0RBE
|
DE |
|
C
|
Codexis Inc
F:4QK
|
US |
|
Bunge Ltd
NYSE:BG
|
US |
|
Brunswick Corp
NYSE:BC
|
US |
|
S
|
Sumitomo Corp
XBER:SUMA
|
JP |
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals is a specialty drug company that makes prescription medicines for central nervous system disorders, especially attention deficit hyperactivity disorder, epilepsy, migraine, and movement disorders. Its main products are branded medicines sold through pharmacies to patients with prescriptions from doctors. The company earns money when wholesalers and pharmacies buy those drugs and move them into the prescription chain. Its customer base is mostly patients, prescribers, pharmacies, and drug wholesalers, with doctors playing a key role because they decide which treatment to use. Supernus also develops and markets medicines that can be taken on a regular schedule or in specific long-acting forms, which matters in conditions where steady symptom control is important. In some cases, it also works with other drug companies through licensing or commercialization agreements. What makes Supernus different is that it focuses on a narrow set of brain and nervous system conditions rather than a broad menu of medicines. That gives it a business built around a few specialized brands, close relationships with doctors who treat these disorders, and a strong dependence on prescription demand and patent-protected products.
Supernus Pharmaceuticals is a specialty drug company that makes prescription medicines for central nervous system disorders, especially attention deficit hyperactivity disorder, epilepsy, migraine, and movement disorders. Its main products are branded medicines sold through pharmacies to patients with prescriptions from doctors. The company earns money when wholesalers and pharmacies buy those drugs and move them into the prescription chain.
Its customer base is mostly patients, prescribers, pharmacies, and drug wholesalers, with doctors playing a key role because they decide which treatment to use. Supernus also develops and markets medicines that can be taken on a regular schedule or in specific long-acting forms, which matters in conditions where steady symptom control is important. In some cases, it also works with other drug companies through licensing or commercialization agreements.
What makes Supernus different is that it focuses on a narrow set of brain and nervous system conditions rather than a broad menu of medicines. That gives it a business built around a few specialized brands, close relationships with doctors who treat these disorders, and a strong dependence on prescription demand and patent-protected products.
Record Revenue: Supernus reported record total revenue of $719 million for 2025, driven by strong growth from its four core products.
Growth Product Momentum: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO together accounted for 76% of Q4 revenue, marking a shift from legacy products.
ONAPGO Supply Resolved: Supply constraints for ONAPGO have been addressed, and new patient initiations have resumed, with the current supplier covering all 2026 guidance needs.
ZURZUVAE Uptake: ZURZUVAE saw rapid prescription growth with a 187% year-over-year increase in Q4 sales and high repeat prescriber rates.
Qelbree Delivers: Qelbree net sales topped $300 million, up 26%, with double-digit prescription growth across adult and pediatric populations.
2026 Outlook: Management guided 2026 total revenue of $840–870 million and expects operating income to range from breakeven to a loss of $30 million.
Strategic Focus: Supernus remains focused on CNS and women's health, pursuing additional revenue-generating or late-stage pipeline assets.
